Systemic Sclerosis Market to Exhibit Growth at a 3% CAGR During the Forecast Period (2026–2036) as Emerging Therapies Expand Treatment Opportunities | DelveInsight
New York, USA, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Systemic Sclerosis Market to Exhibit Growth at a 3% CAGR During the Forecast Period (2026–2036) as Emerging Therapies Expand Treatment Opportunities | DelveInsight
DelveInsight's report sizes the Systemic Sclerosis market at USD 1.9 billion across the 7MM in 2025, with a 3% CAGR forecast through 2036. This growth is driven by increasing disease awareness, advancements in diagnostic capabilities, and the growing focus on developing targeted therapies to address disease heterogeneity, fibrosis, and immune dysregulation. Additionally, the expanding clinical development pipeline, including investigational therapies such as Anifrolumab (SAPHNELO; AstraZeneca), Belimumab (BENLYSTA; GSK), Efzofitimod (aTyr Pharma), Nemolizumab (Galderma), Nerandomilast (BI 1015550; Boehringer Ingelheim), and others, is expected to drive market growth across the 7MM from 2026–2036, creating significant commercial opportunities as innovative treatment candidates advance toward potential regulatory approval and launch.
Recently published Systemic Sclerosis Market Insights report includes a comprehensive understanding of current treatment practices, systemic sclerosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Systemic Sclerosis Market Summary
- The market size for systemic sclerosis was found to be USD 1.9 billion in the 7MM in 2025.
- The United States accounted for about 55% of the 7MM market in 2025, the largest share of any market covered.
- The diagnosed prevalent cases of systemic sclerosis in the 7MM were estimated to be ~ 232K cases in 2025.
- Leading systemic sclerosis companies, such as AstraZeneca, GSK, Galderma, aTyr Pharma, Boehringer Ingelheim, Cabaletta Bio, Zura Bio, Merck, Prometheus Biosciences, argenx, Artiva Biotherapeutics, Mitsubishi Tanabe Pharma, and others, are developing new systemic sclerosis treatment drugs that can be available in the systemic sclerosis market in the coming years.
- The promising systemic sclerosis therapies in clinical trials include Anifrolumab (SAPHNELO), Belimumab (BENLYSTA), Nemolizumab, Efzofitimod, Nerandomilast (BI 1015550), CABA-201, Tibulizumab (ZB-106), Tulisokibart (MK-7240/PRA023), Efgartigimod, AlloNK (AB-101) + rituximab, inebilizumab (UPLIZNA/MT-0551), and others.
Download the free sample page to discover new treatments for systemic sclerosis @ https://www.delveinsight.com/report-store/systemic-sclerosis-market

Shikha Bhardwaj, Associate Consultant of Forecasting at DelveInsight, said that emerging targeted immunomodulatory, antifibrotic, and cellular therapies are expected to gain uptake based on efficacy, organ-specific benefits, safety, convenience, and differentiation from existing treatments. Adoption is likely to be gradual due to disease heterogeneity, varied organ involvement, patient selection, and established treatment practices, while improved diagnosis, stratification, and clinical experience are expected to support market growth through 2036.
Key Factors Driving the Growth of the Systemic Sclerosis Market
- Increasing Prevalence and Disease Awareness: Growing recognition of systemic sclerosis is contributing to improved diagnosis and treatment rates. Increasing awareness among healthcare professionals and patients is supporting earlier intervention and greater demand for effective disease management options.
- Advancements in Targeted Therapy Development: Growing research into the immunological, inflammatory, and fibrotic pathways involved in systemic sclerosis is supporting the development of targeted treatments. Emerging approaches aim to address disease mechanisms more precisely, potentially improving efficacy and safety compared with conventional immunosuppressive therapies.
- Expanding Clinical Development Pipeline: Increasing investment in clinical research is advancing potential therapies for systemic sclerosis, particularly for skin fibrosis and interstitial lung disease associated with the condition. The development of novel biologics, antifibrotic agents, and immunomodulatory therapies including Anifrolumab (SAPHNELO), Belimumab (BENLYSTA), Nemolizumab, Efzofitimod, Nerandomilast (BI 1015550), CABA-201, Tibulizumab (ZB-106), Tulisokibart (MK-7240/PRA023), Efgartigimod, AlloNK (AB-101) + rituximab, inebilizumab (UPLIZNA/MT-0551), and others is expected to expand future treatment options and support market growth.
- Growing Investment in Rare Disease Research and Drug Development: Pharmaceutical and biotechnology companies such as AstraZeneca, GSK, Galderma, aTyr Pharma, Boehringer Ingelheim, Cabaletta Bio, Zura Bio, Merck, Prometheus Biosciences, argenx, Artiva Biotherapeutics, Mitsubishi Tanabe Pharma, and others are increasingly exploring innovative treatments for rare autoimmune and fibrotic diseases, including systemic sclerosis. Research collaborations, clinical trial investments, and regulatory incentives for rare disease drug development may accelerate therapeutic innovation and contribute to the expansion of the market.
- Increasing Focus on Personalized Treatment Approaches: Systemic sclerosis varies considerably in its clinical presentation, disease progression, and organ involvement. Greater understanding of disease subtypes, patient-specific risk factors, and biomarkers is supporting more individualized treatment strategies, potentially improving therapeutic outcomes and encouraging the adoption of specialized treatment options.
Download the report to understand the top emerging systemic sclerosis drugs @ Systemic Sclerosis Clinical Trials
Systemic Sclerosis Market Analysis
- The current treatment landscape for systemic sclerosis is guided by the affected organs and disease progression, incorporating immunomodulatory, antifibrotic, vasculopathy-targeted, and supportive therapies.
- Nintedanib (OFEV), approved by the FDA in 2019, and tocilizumab (ACTEMRA), approved in 2021, help slow the decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
- Tocilizumab was the first IL-6-targeted biologic approved for this indication. Other therapies, including mycophenolate mofetil and rituximab, are also used depending on individual disease manifestations.
- The expiration of key patents for tocilizumab has facilitated the introduction of biosimilar alternatives, while the conclusion of nintedanib's primary exclusivity period is creating opportunities for generic competition.
- These developments are expected to reshape the treatment landscape by improving affordability and increasing access to cost-effective therapeutic options.
- The FDA has approved the first generic nintedanib applications from major pharmaceutical manufacturers, including Cipla, Apotex, and Dr. Reddy's.
- The resulting competitive pressure is anticipated to drive price erosion and affect branded product revenues over the next 24 months, although Boehringer Ingelheim continues to pursue strategies to maintain and protect its market position.
- Meanwhile, the systemic sclerosis pipeline is advancing toward targeted therapies with the potential to modify disease progression.
- Key candidates include AstraZeneca's anifrolumab (SAPHNELO), GSK's belimumab (BENLYSTA), aTyr Pharma's efzofitimod, Boehringer Ingelheim's nerandomilast and avenciguat, Mitsubishi Tanabe Pharma's inebilizumab (UPLIZNA/MT-0551), and Galderma's nemolizumab.
- These investigational and emerging treatment approaches focus on addressing fibrosis, inflammation, and progressive organ involvement, with the potential to expand therapeutic options and improve outcomes for patients with systemic sclerosis.
Systemic Sclerosis Competitive Landscape
Some of the systemic sclerosis drugs under development include Anifrolumab (SAPHNELO; AstraZeneca), Belimumab (BENLYSTA; GSK), Efzofitimod (aTyr Pharma), Nemolizumab (Galderma), Nerandomilast (BI 1015550; Boehringer Ingelheim), CABA-201 (Cabaletta Bio), Tibulizumab (ZB-106; Zura Bio), Tulisokibart (MK-7240/PRA023; Merck/Prometheus Biosciences), Efgartigimod (argenx), AlloNK (AB-101) + rituximab (Artiva Biotherapeutics), inebilizumab (UPLIZNA/MT-0551; Mitsubishi Tanabe Pharma), and others.
GSK’s Belimumab is a B-lymphocyte stimulator (BLyS)-specific inhibitor that binds to soluble BLyS, a protein found at elevated levels in patients with systemic autoimmune diseases. The drug is currently being investigated in Phase II/III clinical trials for systemic sclerosis-associated interstitial lung disease (SSc-ILD). In February 2023, the US FDA granted belimumab Orphan Drug Designation (ODD) for the potential treatment of systemic sclerosis.
AstraZeneca’s Anifrolumab is a first-in-class, fully human monoclonal antibody that targets subunit 1 of the type I interferon receptor (IFNAR1). It is currently being evaluated in the Phase III DAISY study involving adults with systemic sclerosis. In October 2013, the US FDA granted anifrolumab Orphan Drug Designation (ODD) for the treatment of systemic sclerosis.
Galderma’s Nemolizumab is a monoclonal antibody that targets interleukin-31 receptor alpha (IL-31Rα), a neuroimmune cytokine receptor involved in itch signaling, inflammation, and skin barrier dysfunction. Galderma continues to explore the drug's therapeutic potential across additional indications, including systemic sclerosis and chronic pruritus of unknown origin (CPUO). In June 2025, the company announced the initiation of two clinical trials to evaluate the efficacy and safety of nemolizumab in patients with systemic sclerosis and CPUO. Both conditions are associated with substantial unmet medical needs, compromised quality of life, poor clinical outcomes, and potentially life-threatening complications.
The anticipated launch of these emerging therapies are poised to transform the systemic sclerosis market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the systemic sclerosis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
See the systemic sclerosis pipeline by phase and company @ Systemic Sclerosis Medications
Recent Developments in the Systemic Sclerosis Market
- In August 2026, aTyr Pharma announced that enrollment had been completed in the Phase II EFZO-CONNECT study evaluating efzofitimod in patients with limited or diffuse Systemic sclerosis-associated interstitial lung disease. Topline results are expected in the first quarter of 2027, supporting continued development of efzofitimod as a potential disease-modifying therapy for Systemic Sclerosis-ILD.
- In July 2026, Galderma initiated the Phase II study of nemolizumab in adults with Systemic Sclerosis. The randomized study is evaluating the effect of nemolizumab on cutaneous thickness at Week 52, with a planned 154 participants and a 156-week extension to assess longer-term safety and efficacy.
- In July 2026, Boehringer Ingelheim initiated a Phase III study of nerandomilast (BI 1015550) in adults with Systemic Sclerosis. The randomized, placebo-controlled study is evaluating whether oral nerandomilast can improve disease outcomes and slow progression, with assessments including skin thickening, lung function, and internal-organ involvement.
| Systemic Sclerosis Market Report Metrics | Details |
| Study Period | 2022–2036 |
| Coverage | 7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. |
| Systemic Sclerosis Market CAGR | 3% |
| Systemic Sclerosis Market Size in 2025 | USD 1.9 Billion |
| Key Systemic Sclerosis Companies | AstraZeneca, GSK, Galderma, aTyr Pharma, Boehringer Ingelheim, Cabaletta Bio, Zura Bio, Merck, Prometheus Biosciences, argenx, Artiva Biotherapeutics, Mitsubishi Tanabe Pharma, Zenyaku Kogyo, Chugai Pharmaceutical, and others |
| Key Systemic Sclerosis Therapies | Anifrolumab (SAPHNELO), Belimumab (BENLYSTA), Nemolizumab, Efzofitimod, Nerandomilast (BI 1015550), CABA-201, Tibulizumab (ZB-106), Tulisokibart (MK-7240/PRA023), Efgartigimod, AlloNK (AB-101) + rituximab, inebilizumab (UPLIZNA/MT-0551), OFEV, RITUXAN, and others |
What’s the Systemic Sclerosis Market Report Includes?
DelveInsight's Systemic Sclerosis Market Report delivers executive-level intelligence on the evolving market landscape, integrating epidemiology (Systemic Sclerosis Total Diagnosed Prevalent Cases, Systemic Sclerosis Disease Subset-specific Diagnosed Prevalent Cases, Systemic Sclerosis Age-specific Diagnosed Prevalent Cases, Systemic Sclerosis Organ Involvement-specific Diagnosed Prevalent Cases, Systemic Sclerosis Severity by Organ Damage Diagnosed Prevalent Cases, Systemic Sclerosis Severity by Skin Thickness Diagnosed Prevalent Cases, and Systemic Sclerosis Treated Cases), treatment practices, competitive dynamics, emerging therapies, and market forecasts across the major markets through 2036. Built on a rigorous methodology combining comprehensive secondary research, primary interviews with key opinion leaders and industry experts, and proprietary patient-based forecasting models, the report provides a reliable foundation for strategic planning. Designed for pharmaceutical and biotech executives, it enables informed decisions on portfolio strategy, business development, market entry, investment prioritization, and commercial planning.
Request a free sample @ Systemic Sclerosis Market Report
Table of Contents
| 1 | Systemic Sclerosis Market Key Insights |
| 2 | Systemic Sclerosis Market Report Introduction |
| 3 | Executive Summary |
| 4 | Key Events |
| 5 | Epidemiology and Market Methodology of Systemic Sclerosis |
| 6 | Systemic Sclerosis Market Overview at a Glance |
| 6.1 | Clinical Landscape Analysis (By Molecule Type, Phase, and Route of Administration [ROA]) |
| 6.2 | Market Share of Systemic Sclerosis By Therapies (%) in the 7MM in 2025 |
| 6.3 | Market Share of Systemic Sclerosis By Therapies (%) in the 7MM in 2036 |
| 7 | Disease Background And Overview of Systemic Sclerosis |
| 7.1 | Introduction |
| 7.2 | Causes |
| 7.3 | Signs And Symptoms |
| 7.4 | Diagnosis |
| 7.5 | Treatment and Management |
| 8 | Epidemiology and Patient Population of Systemic Sclerosis |
| 8.1 | Key Findings |
| 8.2 | Assumption and Rationale |
| 8.3 | Systemic Sclerosis Total Diagnosed Prevalent Cases in the 7MM |
| 8.4 | The United States |
| 8.4.1 | Systemic Sclerosis Total Diagnosed Prevalent Cases in the United States |
| 8.4.2 | Systemic Sclerosis Disease Subset-specific Diagnosed Prevalent Cases in the United States |
| 8.4.3 | Systemic Sclerosis Age-specific Diagnosed Prevalent Cases in the United States |
| 8.4.4 | Systemic Sclerosis Organ Involvement-specific Diagnosed Prevalent Cases in the United States |
| 8.4.5 | Systemic Sclerosis Severity by Organ Damage Diagnosed Prevalent Cases in the United States |
| 8.4.6 | Systemic Sclerosis Severity by Skin Thickness Diagnosed Prevalent Cases in the United States |
| 8.4.7 | Systemic Sclerosis Treated Cases in the United States |
| 8.5 | EU4 and the UK |
| 8.6 | Japan |
| 9 | Patient Journey of Systemic Sclerosis |
| 10 | Marketed Therapies of IIM |
| 10.1 | Marketed Drugs Competitive Landscape of Systemic Sclerosis |
| 10.2 | Nintedanib (OFEV): Boehringer Ingelheim |
| 10.2.1 | Product Description |
| 10.2.2 | Regulatory Milestones |
| 10.2.3 | Other Developmental Activities |
| 10.2.4 | Summary of Pivotal Trial |
| 10.2.5 | Safety and Efficacy |
| 10.2.6 | Analyst Views |
| 10.3 | Rituximab (RITUXAN): Zenyaku Kogyo/Chugai Pharmaceutical |
| List to be continued…… | |
| 11 | Emerging Therapies |
| 11.1 | Emerging Competitive Landscape of Systemic Sclerosis |
| 11.2 | Belimumab (BENLYSTA): GSK |
| 11.2.1 | Product Description |
| 11.2.2 | Other Developmental Activities |
| 11.2.3 | Clinical Development |
| 11.2.3.1 | Clinical Trial Information |
| 11.2.4 | Safety and Efficacy |
| 11.2.5 | Analyst Views |
| 11.3 | Anifrolumab (SAPHNELO) : AstraZeneca |
| 11.4 | Nemolizumab: Galderma |
| List to be continued…… | |
| 12 | Systemic Sclerosis: Seven Major Market Analysis |
| 12.1 | Key Findings |
| 12.2 | Market Outlook of Systemic Sclerosis |
| 12.3 | Conjoint Analysis of Systemic Sclerosis |
| 12.4 | Key Market Forecast Assumptions |
| 12.5 | Total Market Size of Systemic Sclerosis in the 7MM |
| 12.6 | Market Size of Systemic Sclerosis by Therapies in the 7MM |
| 12.7 | The United States Systemic Sclerosis Market |
| 12.7.1 | Total Market Size of Systemic Sclerosis in the United States |
| 12.7.2 | Market Size of Systemic Sclerosis by Therapies in the United States |
| 12.8 | EU4 and the UK Systemic Sclerosis Market |
| 12.9 | Japan Systemic Sclerosis Market |
| 13 | Unmet Needs of Systemic Sclerosis |
| 14 | SWOT Analysis of Systemic Sclerosis |
| 15 | KOL Views of Systemic Sclerosis |
| 16 | Market Access and Reimbursement |
| 16.1 | The US |
| 16.2 | In EU4 and the UK |
| 16.3 | Japan |
| 16.4 | Summary and Comparison of Market Access and Pricing Policy Developments in 2025 |
| 16.5 | Market Access and Reimbursement of Systemic Sclerosis Therapies |
| 17 | Bibliography |
| 18 | Systemic Sclerosis Market Report Methodology |
Related Reports
Systemic Sclerosis Clinical Trial Analysis
Systemic Sclerosis Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key systemic sclerosis companies, including Eicos Sciences, Beijing Continent Pharmaceutical, Kyowa Kirin, Cytori therapeutics, Corbus Pharmaceuticals, Zenyaku Kogyo, Sanofi, Bayer, ASKA Pharmaceutical, Emerald Health Pharmaceuticals, United Therapeutics, Cumberland Pharmaceuticals, ILTOO Pharma, Horizon Pharmaceuticals, Janssen Biotech, Gesynta Pharma, Certa Therapeutics, Vicore Pharma, Seagen, CSL Behring, arGentis Pharmaceuticals, Mitsubishi Tanabe Pharma, Kadmon Pharmaceuticals, GlaxoSmithKline, Bristol-Myers Squibb, Camurus, Pfizer, Regeneron Pharmaceuticals, Regeneron Pharmaceuticals, Castle Creek Biosciences, Talaris Therapeutics, Viela Bio, Formation Biologics, Horizon Therapeutics, Chemomab Therapeutics, AnaMar, Atlantic Healthcare, D&D Pharmatech, Acceleron Pharma, Riptide Bioscience, Timber Pharmaceuticals, Tvardi Therapeutics, Accuitis Pharmaceuticals, AKL Research and Development, iBio, Blade Therapeutics, Cantargia, BriaCell Therapeutics, Leadiant Biosciences, and others.
Diffuse Cutaneous Systemic Sclerosis Market
Diffuse Cutaneous Systemic Sclerosis Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key diffuse cutaneous systemic sclerosis companies, including Kadmon Corporation, Kyowa Kirin Co., Ltd., Gesynta Pharma AB, Acceleron Pharma Inc, Mitsubishi Tanabe Pharma Development, Emerald Health Pharmaceuticals, Cumberland Pharmaceuticals, Horizon Therapeutics Ireland DAC, CSL Behring, Seagen Inc., Janssen Pharmaceutical, Prometheus Biosciences, Inc., GlaxoSmithKline, Certa Therapeutics, and others.
Diffuse Cutaneous Systemic Sclerosis Clinical Trial Analysis
Diffuse Cutaneous Systemic Sclerosis Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key diffuse cutaneous systemic sclerosis companies, including Kadmon Pharmaceuticals, Talaris Therapeutics, Horizon Therapeutics, Mitsubishi Tanabe Pharma, Takeda Oncology, Seagen, and others.
Systemic Sclerosis-associated Lung Disease Market
Systemic Sclerosis-associated Lung Disease Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key systemic sclerosis-associated lung disease companies including Genentech Inc., Boehringer Ingelheim, Prometheus Biosciences Inc., Roche, Acceleron Pharma, Talaris Therapeutics, Kadmon Corporation, and others.
Systemic Sclerosis-associated Lung Disease Clinical Trial Analysis
Systemic Sclerosis-associated Lung Disease Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key systemic sclerosis-associated lung disease companies, including Genentech Inc., Boehringer Ingelheim, Prometheus Biosciences Inc., Roche, Acceleron Pharma, Talaris Therapeutics, Kadmon Corporation, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us Shruti Thakur info@delveinsight.com +14699457679 www.delveinsight.com
© Copyright Globe Newswire, Inc. All rights reserved. The information contained in this news report may not be published, broadcast or otherwise distributed without the prior written authority of Globe Newswire, Inc.




